Portalvein reconstruction with a cadaveric descending thoracic aortic homograft

Improvements in chemoradiotherapy have rendered complex pancreatic cancers involving the portal vein (PV) amenable to resection. PV reconstruction (PVR) is an essential component. Various conduits have been proposed; however, the optimal choice remains unknown. Fourteen patients underwent PVR with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaffey, Ann C., Zhang, Jason, Lee, Major K., Roses, Robert, Jackson, Benjamin M., Quatromoni, Jon G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Innovative technique
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133702/
https://www.ncbi.nlm.nih.gov/pubmed/35647419
http://dx.doi.org/10.1016/j.jvscit.2022.04.001
Descripción
Sumario:Improvements in chemoradiotherapy have rendered complex pancreatic cancers involving the portal vein (PV) amenable to resection. PV reconstruction (PVR) is an essential component. Various conduits have been proposed; however, the optimal choice remains unknown. Fourteen patients underwent PVR with a cadaveric descending thoracic aortic homograft from 2014 to 2020. The primary diagnosis was pancreatic cancer. The splenic vein was ligated in seven patients (50%). The 30-day and 3-, 12-, and 24-month primary patency rates were 100%, 86%, 76%, and 76%, respectively. We found a cadaveric descending thoracic aortic homograft is an excellent conduit for PVR, given the optimal size, rapidly availability, favorable risk profile, and absence of harvest site complications.

Ejemplares similares